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Abstract Based on amino acid sequence information from
purified mitochondrial thymidine kinase (TK2), a cDNA of 1930
bp was cloned, containing an open reading frame encoding 232
amino acid residues starting with the N-terminal sequence
determined from the native human protein preparation. Northern
blot analysis with the cDNA coding region demonstrated several
TK2 mRNAs, with 2 and 4 kb forms present in many tissues. We
also characterised N-terminally truncated (starting at position
18) human TK2 with pharmacologically important antiviral and
cytostatic nucleoside analogues. Results were highly similar to
those with the native TK2 preparation. The anti-leukaemic drug
arabinosyl cytosine is phosphorylated. The antitumour drug
difluorodeoxycytidine and its metabolite difluorodeoxyuridine
are good substrates, with Km values of 66 and 29 WM,
respectively, and a relative Vmax of 0.6 compared to that of
thymidine. Negative cooperativity was found with thymidine and
the anti-HIV drug 3P-azidothymidine, but the reaction followed
Michaelis-Menten kinetics with deoxycytidine, arabinosyl cyto-
sine, and arabinosyl thymine. The results demonstrate a broad
substrate specificity and complex kinetics, and suggest a role for
TK2 in the activation of chemotherapeutic nucleoside analogues.
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1. Introduction
Mitochondrial thymidine kinase (TK2) phosphorylates py-
rimidine deoxynucleosides and their analogues to the corre-
sponding nucleoside monophosphates, using a nucleoside tri-
phosphate as phosphate donor. There are two thymidine
kinases in animal cells, a cytosolic (TK1) and a mitochondrial
(TK2) enzyme, with di¡erent properties [1^3]. TK1, which
was cloned in 1983 [4], is expressed only in S-phase cells, while
TK2 is expressed in all tissues in proportion to the mitochon-
drial content of the cell type. In many resting cells, such as
nerve and muscle cells, TK2 is the only pyrimidine deoxynu-
cleoside phosphorylating enzyme expressed. In these tissues,
where de novo synthesis of DNA precursors is undetectable
[3], TK2 is likely to be responsible for the supply of deoxy-
ribonucleotides required for mitochondrial DNA synthesis.
The physiological role of TK2 is not well de¢ned but in cells
with no TK1 activity, TK2-mediated phosphorylation of thy-
midine (dThd) leads to a product apparently incorporated
into mitochondrial DNA [5]. Similarly, phosphorylation of
3P-azidothymidine (AZT) in monocytes/macrophages and pe-
ripheral blood lymphocytes intrinsically lacking TK1 activity
is dependent on TK2, which is important for the e⁄cacy of
anti-HIV nucleoside chemotherapy [6,7].
The TK2 enzyme has been puri¢ed from human spleen,
brain and lymphoblasts [3,8], the gene has been localised to
chromosome 16 [9] and a cDNA cloning has been reported
[10]. However, the TK2 protein described from that clone [10]
shows di¡erences from the puri¢ed protein in an N-terminal
segment and in substrate speci¢city. We have carried through
another cloning based on sequence information from human
and bovine brain TK2 and have cloned human TK2 cDNA in
a form compatible with the native enzyme, expressed an ac-
tive, truncated TK2 protein at high level in Escherichia coli,
and characterised enzymatically both the recombinant and
native TK2 forms with antiviral and cytostatic analogues
not previously known to be substrates for TK2.
2. Materials and methods
2.1. Puri¢cation and amino acid sequence analysis of TK2
Brain tissues were homogenised and TK2 was puri¢ed [8,11]. Calf
brain was obtained freshly frozen from a local slaughterhouse. Hu-
man brain was obtained from the Department of Pathology, Karo-
linska Hospital, with ethical permit. SDS-polyacrylamide gel electro-
phoresis of the fractions after hydroxylapatite revealed the presence of
one polypeptide of 29 kDa, corresponding to TK2. Amino acid se-
quencer analysis (ABI 470) of the puri¢ed human TK2 yielded the
N-terminal sequence VQRYAWPPDKEQEKEKKSVIXVEGNIAS.
Internal sequence information for three peptides, YVFVENLYR,
XXPETXYQR and MLEXF, of bovine TK2 was obtained from ma-
terial excised from a Coomassie-stained SDS gel preparation, sub-
jected to in-gel trypsin cleavage and subsequent peptide isolation by
reverse phase liquid chromatography [12].
2.2. Cloning of TK2 cDNA
Parts of two of the TK2 amino acid sequences, EGNIA (from the
human N-terminal segment) and YVFVENL (from one of the bovine
internal segments), were highly similar to the N-terminal region of
human deoxycytidine kinase [13] and selected for oligonucleotide syn-
thesis. The sense primer mixture was 5P-ggaattccGTNGAA(G)G-
GNAAT(C)ATT(CA)GC, and the antisense primer mixture was
5P-gcgtcgACA(G)TTT(C)TCNACA(G)AANACA(G)TA, where N
denotes T+A+G+C. An RT-PCR reaction was used to amplify a
TK2-speci¢c DNA fragment of 276 bp with bovine brain mRNA as
template (prepared with a polyA tract mRNA isolation system from
Promega). The ampli¢ed PCR fragment was puri¢ed, cloned into the
Bluescript SK3 vector, and sequenced. A human brain Lambda ZAP
cDNA library (Stratagene) was screened with the 276 bp fragment as
probe. One positive V phage was isolated, the cDNA insert was sub-
cloned into the Bluescript vector, and both strands were sequenced.
Human brain mRNA (Clontech) was used in an RT reaction (5P/3P-
RACE kit from Boehringer Mannheim) with a TK2-speci¢c primer to
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amplify the 5P end of TK2 cDNA. The ampli¢ed PCR fragments were
cloned into the PCR 2.1 vector (Invitrogen) and sequenced. The nu-
cleotide sequence of the TK2 cDNA was deposited in GenBank/
EMBL databases with accession number Y10498.
2.3. Northern blot analysis
Human Multi-Tissue Blots (Clontech) were probed with the coding
region of the TK2 cDNA (680 bp) in 5USSPE, 10UDenhardt’s sol-
ution, 100 Wg/ml freshly denatured salmon sperm DNA, 2% SDS and
50% formamide at 42‡C for 20 h, washed in 0.2USSC, 0.1% SDS
twice at 60‡C, and autoradiographed.
2.4. Expression of N-terminally truncated TK2 protein
TK2 cDNA, starting corresponding to Ser-18 in Fig. 4, was PCR
ampli¢ed and subcloned into the pET-14b expression vector (Nova-
gen). The fusion protein contains an N-terminal 6UHis tag and a
thrombin cleavage site. The resulting construct was transformed
into E. coli BL21 (DE3) pLysS cells, and induction was performed
for 2 h in the presence of 1 mM IPTG at 37‡C. Bacteria were lysed in
50 mM Tris-HCl, pH 7.6, 0.5 M NaCl, 0.5% NP-40, 140 WM phenyl-
methylsulphonyl £uoride by freezing and thawing. The lysate was
centrifuged at 100 000Ug for 90 min at 4‡C. TK2 was puri¢ed by
metal a⁄nity (His Bind resin, Novagen) column chromatography
and eluted with 0.15 M imidazole in 50 mM Tris-HCl, pH 7.9, and
0.5 M NaCl. Dithiothreitol (2 mM) and glycerol (20%) were added to
the puri¢ed TK2. To remove the N-terminal His tag, thrombin (No-
vagen) was added in a ratio of 5 units to 1 mg protein, and incubated
at 22‡C overnight.
2.5. Enzyme assays and kinetic parameters
Nucleoside kinase activity was determined either by initial velocity
measurements with four-time samples in a DE81 paper assay using
tritium-labelled substrates [8] or by a phosphoryl transfer assay [14].
One unit is de¢ned as 1 nmol dTMP formed per min. Substrate
kinetics were analysed using a broad substrate range to identify devi-
ation from hyperbolic kinetics. Cooperative kinetics were analysed by
Hill plots, with the maximal velocity determined by non-linear regres-
sion analysis. The type of kinetics was identi¢ed using Hofstee plots
for negative cooperativity and double reciprocal plots for hyperbolic
or positive cooperativity.
3. Results
3.1. Molecular cloning of TK2 cDNA
TK2, more than 95% pure, was obtained from human and
bovine tissue extracts by DEAE-chromatography followed by
a⁄nity chromatography and hydroxyl apatite chromatogra-
phy [8,11]. Human brain TK2 gave an N-terminal 28 residue
amino acid sequence. To obtain internal peptide sequence in-
formation, puri¢ed bovine brain TK2 was used and subjected
to SDS-polyacrylamide gel electrophoresis. The protein band
was excised, treated with trypsin and the resulting peptides
were separated by reverse phase liquid chromatography. The
human and bovine sequences obtained are given in Section
2.2. Based on two sequences that showed homology with a
region of the human dCK sequence [13], two primer mixtures
were designed and used in an RT-PCR reaction starting with
bovine brain mRNA. A DNA fragment of the expected
length, 276 bp, was obtained and then used as probe to screen
a human brain cDNA library. There was only one positive
plaque of 1U106 screened and its cDNA insert was 1325 bp.
Cloning of 5P-RACE PCR products with mRNA from human
brain and liver showed the same 1325 bp fragment sequence.
Searches in the EST database revealed that there are more
than 30 EST sequences showing nearly 100% identity to the
¢rst 365 bp of the 1325 bp TK2 cDNA. Later studies have
shown that the 365 bp are part of an intron sequence con-
taining repetitive elements (L. Wang et al., unpublished). PCR
reactions performed using high temperature reverse transcrip-
tion (to reduce the in£uence of mRNA secondary structure)
and an oligonucleotide mixture deduced from the eight N-
terminal amino acids of human brain TK2 gave a 150 bp
fragment. This fragment was found, after cloning and se-
quence analysis, to encode the correct N-terminal segment
of TK2. Thus, a TK2 cDNA with a total length of 1953 bp
could be isolated, containing an open reading frame of 699
bp. All the characterised peptide sequences, from both human
brain and bovine brain TK2, were identi¢ed in this TK2
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Fig. 1. Northern blot analysis of TK2 mRNA levels in human tis-
sues, using a multiple tissue Northern blot from Clontech with 2 Wg
mRNA in each lane and a 680 bp TK2 cDNA as probe.
Fig. 2. The activity of recombinant TK2 at varied dThd (open
circles) and dCyd (closed circles) concentrations. The data are plot-
ted as v versus v/s, where v is the initital velocity in units/mg, and s
is the deoxynucleoside concentration in WM. The inset shows Hill
plots of the same data, where the dotted line indicates the Hill coef-
¢cient of 1.0.
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cDNA (but with one species di¡erence, Ile at position 109 in
human TK2 and Val in bovine TK2). However, the present
human TK2 cDNA (Y10498) di¡ers from the TK2 cDNA
reported earlier [10].
The human TK2 gene showed a complex transcription pat-
tern as determined by Northern blot analysis using TK2
cDNA as probe (Fig. 1). Multiple transcripts exist in several
tissues, with two major bands at 4.0 kb and 2.2 kb. In testis,
ovary, and thymus, there is a longer transcript of about 5.0 kb
and in testis also a shorter transcript of about 1.35 kb. The
expression of the 4.0 kb transcript (Fig. 1) occurs at similar
levels in several tissues, with the exception of low values in
colon and peripheral blood leukocytes. The levels of the 2.2
kb transcript is about 20^50% of that of the 4.0 kb transcript
in the same tissue, and the levels of all four TK2 transcripts
are several-fold higher in testis and ovary.
3.2. Enzymatic characterisation of recombinant and native TK2
with natural substrates and antiviral and cytostatic
analogues
Using the pET system, expression of N-terminally truncated
TK2 (starting at position 18 of the native protein) resulted in
a fully active enzyme. The kinetics of this recombinant TK2
and of the enzyme prepared from leukaemic spleen were in-
vestigated. As demonstrated by the results in Fig. 2 and Table
1, the recombinant TK2 phosphorylated both dThd and de-
oxycytidine (dCyd) but with negative cooperativity (n6 1) for
dThd and hyperbolic (n = 1) for dCyd. CTP was an e⁄cient
phosphate donor with about 60% of the capacity of ATP, and
dCyd was a poor inhibitor of the TK2 activity (Ki 630 WM),
whereas dThd was an e⁄cient inhibitor of the deoxycytidine
kinase activity (Ki 6 WM). These characteristics were similar to
those observed earlier with spleen TK2 [8]. Furthermore, re-
combinant TK2 also showed similar capacity to phosphoryl-
ate pyrimidine deoxynucleosides, pyrimidine arabinosides, and
their analogues (Table 2). The anti-hepatitis B analogue 1-(2P-
deoxy-2P-£uoro-1-L-D-arabinofuranosyl)-5-iodouracil (FIAU)
is as good a substrate as dThd for both bovine brain TK2
and recombinant human TK2 [14]. The kinetic pattern with
1-L-D-arabinofuranosylcytosine (AraC) was identical for re-
combinant and spleen TK2 (Fig. 3), and hyperbolic as indi-
cated by the straight lines in the double reciprocal plots and n
values of 1 in the Hill plots (inset, Fig. 3). Because of lack of
radioactive 2P-di£uoro-deoxycytidine (dFdC) and 2P-di£uoro-
deoxyuridine (dFdU), those analogues were tested with the
phosphoryl transfer assay using [Q-32P]ATP. This assay gave
kinetic parameters similar to those with the radioactive nu-
cleosides, although the Vmax values were approximately half
of those in Table 1. The Km values for dThd, dCyd, dFdC and
dFdU were 4, 7, 66 and 29 WM, respectively.
The anticancer drug 5-£uorodeoxyuridine (FdUrd) was also
phosphorylated, as well as the antiherpes compound 5-(2-bro-
movinyl)-2P-deoxyuridine (BVdU). Previous investigations
with native TK2 have shown that the anti-HIV drug AZT is
phosphorylated although with low e⁄ciency [8]. This ability
was also found with the recombinant TK2 (Table 1). The
maximal velocities were nearly identical for the two enzymes.
Furthermore, a biphasic Hofstee plot and a Hill coe⁄cient
below 1 with the recombinant TK2 showed negative cooper-
ativity, as with native TK2 [8]. Both 2P,3P-didehydrothymidine
(D4T) and 2P,3P-dideoxycytidine (ddCyd) have been recently
registered as anti-HIV drugs [15] and as with puri¢ed TK2 [8]
they showed very low activity with the recombinant TK2.
4. Discussion
The capacity of resting cells to phosphorylate pyrimidine
deoxynucleosides relies on TK2 and the e⁄cacy or side e¡ects
of antiviral therapy are in part governed by the properties of
this enzyme. A human TK2 cDNA was now cloned using
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Fig. 3. The activity of recombinant TK2 (triangles) and human
spleen TK2 (circles) at varied concentrations of AraC. The data are
plotted as double reciprocal plots of 1/v versus 1/s. The inset shows
Hill plots of the same data, where the dotted line indicates a Hill
coe⁄cient of 1.0.
Fig. 4. N-terminal amino acid sequences of the present TK2 and a variant previously reported (isoform A in [10]). Underlined amino acids are
those determined from human brain TK2 and the bold letters indicate di¡erences between the published [10] TK2 and the TK2 described here.
The arrows indicate positions of the exon intron boundaries.
Table 1
Kinetic parameters of native and recombinant human TK2 with
phosphate acceptors






dThd 16 (n, 0.4) 55 16 (n, 0.5) 35
dCyd 26 34 36 25
AraC 820 0.7 800 0.8
AraT 16 41 39b 30
AZT 33 (n, 0.3) 1 90 (n, 0.4) 0.4
In all kinetic experiments, the variation is less than 20% and in those
cases where the enzyme displays negative cooperativity, the Hill con-
stant (n) is given.
aVmax is in U/mg protein and Km in WM.
bData from ArneŁr et al. [6].
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amino acid sequence information from puri¢ed human and
bovine brain TK2. This TK2 cDNA contains an open reading
frame of 699 bp encoding 232 amino acid residues, and a 1264
bp 3P-untranslated sequence including a polyadenylation sig-
nal followed by a polyA tail. All the peptide sequences deter-
mined from puri¢ed TK2 were found in the deduced coding
sequence. Another cDNA for human TK2 has been reported
[10]. The cloning was then achieved by identi¢cation of EST
sequences which showed homology to deoxycytidine kinase,
and use of that information with RACE protocols to amplify
5P- and 3P-adjoining regions. Two forms of TK2 cDNAs were
then found, one form claimed to encode full-length TK2.
However, that TK2 cDNA shows a sequence identical to
the one reported here only from the nucleotide which encodes
Asp-9, while the present cDNA matches the protein sequence
of native puri¢ed TK2. In addition, Ser-28 in the TK2 cDNA
presented here matches the protein sequence but not the pre-
viously deduced sequence [10]. In spite of a cDNA corre-
sponding to the full-length mature protein, the present TK2
cDNA is incomplete, most likely because of the fact that the
5P part contains several unusual features with repetitive ele-
ments which make it unsuitable for reverse transcription.
There is a splice site where the previous sequence [10] and
the one reported here di¡er (Fig. 4; L. Wang et al., unpub-
lished) and this may perhaps explain the di¡erent cDNA pre-
viously obtained and the absence of coding regions for a mi-
tochondrial target sequence in both the previous and present
TK2 cDNAs. Such a presequence is expected in order to
direct the protein to the mitochondria.
The TK2 gene showed multiple transcripts in most tissues,
including two major bands at 4.0 and 2.2 kb, and in testis,
ovary and thymus longer and shorter transcripts of about 5.0
and 1.35 kb. The di¡erential expression of human TK2
mRNAs with high levels of multiple transcripts in ovary
and testis and low levels in colon and blood leukocytes was
not observed in the earlier study [10]. The existence of several
forms of TK2 mRNA may be derived from alternative usage
of an additional 3P polyadenylation signal or from alternative
splicing of the TK2 mRNA.
Alignment of the human deoxynucleoside kinase sequences
now known shows that the sequence identity of TK2 to de-
oxycytidine kinase and the other mitochondrial purine deox-
ynucleoside phosphorylating enzyme deoxyguanosine kinase is
fairly extensive, about 40% at the amino acid level, while it is
low to TK1, con¢rming that TK2, deoxycytidine kinase and
deoxyguanosine kinase are the kinases evolutionarily most
closely related [16].
The enzyme kinetic characterisation of recombinant and
native TK2 demonstrates that the overall kinetic properties
of the two enzyme forms are indistinguishable. A broad ca-
pacity of recombinant TK2 to phosphorylate pyrimidine ana-
logues was found. Important anticancer and antiviral ana-
logues, such as FdUrd, AraC, dFdC, FIAU and AZT, were
found to be substrates for the enzyme. Notably, AraC was
shown to be a phosphate acceptor for both recombinant and
native TK2. In earlier studies AraC phosphorylation by TK2
was not observed [2,10] and the reason could be the high Km
value and the limited amount of pure enzyme then available.
The implication from the fact that TK2 now is found to be
capable of phosphorylating AraC is that the enzyme may play
a role in activation of AraC.
Gemcitabine (dFdC) is a relatively new deoxycytidine ana-
logue which has shown antitumour activity against ovarian
cancer and non-small-cell lung cancer, and is now in frequent
clinical use [17,18]. The mechanism of inhibition is assumed to
be dependent on dFdCTP incorporation into tumour cell
DNA, and deoxycytidine kinase is regarded to be the enzyme
responsible for the ¢rst rate-limiting step in the anabolism of
this drug. We now observe a relatively high capacity of native
and recombinant TK2 to phosphorylate dFdC. Earlier studies
have shown low expression of deoxycytidine kinase mRNA in
ovary and lung [19], while we ¢nd high levels of TK2 mRNA
in ovaries. These results suggest a role of TK2 in the metab-
olism and pharmacology of dFdC. The conversion of dFdC to
dFdU occurs relatively e⁄ciently in vivo because of the action
of cytidine deaminase, and dFdU has been regarded as a
catabolite that cannot be phosphorylated in cells or tissues
[18]. In accordance with this assumption, TK1 shows no sig-
ni¢cant activity with dFdU (J. Wang and S. Eriksson, unpub-
lished). However, we now ¢nd that TK2 is able to phosphor-
ylate dFdU, and that the e⁄ciency of this substrate with TK2
is approximately 10% of that of Thd. Thus, it is likely that
TK2 contributes to the anabolism of dFdU and may be in-
volved in the e⁄cacy or side e¡ects associated with these types
of analogue. The characterisation of a highly active recombi-
nant TK2 shows the importance of the enzyme in activation
of pharmacologically valuable nucleosides.
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